NCT01394614View on ClinicalTrials.gov

Risk of Narcolepsy Associated With Administration of H1N1 Vaccine

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Narcolepsy
Interventions
BIOLOGICAL

A/H1N1 vaccine

Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.

Trial Locations (1)

H4J 1C5

Sacre-Coeur Hospital, Montreal

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

OTHER

NCT01394614 - Risk of Narcolepsy Associated With Administration of H1N1 Vaccine | Biotech Hunter | Biotech Hunter